Details for New Drug Application (NDA): 022318

✉ Email this page to a colleague

NDA 022318 describes RENVELA, which is a drug marketed by Genzyme and Sanofi and is included in two NDAs. It is available from two suppliers. There are two patents protecting this drug and two Paragraph IV challenges. Additional details are available on the RENVELA profile page.

The generic ingredient in RENVELA is sevelamer carbonate. There are thirty-two drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the sevelamer carbonate profile page.

Summary for 022318

Tradename:	RENVELA
Applicant:	Genzyme
Ingredient:	sevelamer carbonate
Patents:	1

Pharmacology for NDA: 022318

Mechanism of Action	Phosphate Chelating Activity

Suppliers and Packaging for NDA: 022318

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318	NDA AUTHORIZED GENERIC	Winthrop U.S, a business of sanofi-aventis U.S. LLC	0955-1052	0955-1052-90	90 PACKET in 1 BOX (0955-1052-90) / 1 POWDER, FOR SUSPENSION in 1 PACKET (0955-1052-01)
RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318	NDA AUTHORIZED GENERIC	Winthrop U.S, a business of sanofi-aventis U.S. LLC	0955-1054	0955-1054-90	90 PACKET in 1 BOX (0955-1054-90) / 1 POWDER, FOR SUSPENSION in 1 PACKET (0955-1054-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	FOR SUSPENSION;ORAL			Strength	800MG/PACKET
Approval Date:	Aug 12, 2009	TE:	AB	RLD:	Yes
Patent:	⤷ Subscribe	Patent Expiration:	Dec 6, 2030	Product Flag?	Y	Substance Flag?		Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	FOR SUSPENSION;ORAL			Strength	2.4GM/PACKET
Approval Date:	Feb 18, 2009	TE:	AB	RLD:	Yes
Patent:	⤷ Subscribe	Patent Expiration:	Dec 6, 2030	Product Flag?	Y	Substance Flag?		Delist Request?

Expired US Patents for NDA 022318

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Genzyme	RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318-001	Aug 12, 2009	⤷ Subscribe	⤷ Subscribe
Genzyme	RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318-002	Feb 18, 2009	⤷ Subscribe	⤷ Subscribe
Genzyme	RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318-001	Aug 12, 2009	⤷ Subscribe	⤷ Subscribe
Genzyme	RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318-002	Feb 18, 2009	⤷ Subscribe	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.